• Users Online: 55
  • Print this page
  • Email this page
COMMENTARY
Year : 2020  |  Volume : 4  |  Issue : 2  |  Page : 226-229

COVID-19: Neuropsychiatric manifestations and psychopharmacology


1 Department of Psychiatry, Level III Hospital, Goma, DRC
2 Department of Anaesthesiology and Critical Care, Level III Hospital, Goma, DRC
3 Department of Paediatrics, 166 Military Hospital, Jammu, Jammu and Kashmir, India
4 Consultant Radiologist, Ojas Hospital, Panchkula, Haryana, India

Correspondence Address:
Dr. Harpreet Singh Dhillon
Department of Psychiatry, Level III Hospital, Goma
DRC
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/aip.aip_78_20

Rights and Permissions

The COVID-19 pandemic has emerged as one of the major global health crises of recent times. It has posed adverse consequences for people with mental illnesses with its potential to infect patients with existing psychiatric disorders on psychotropic drugs and additionally, spawning psychiatric symptoms in patients infected with COVID-19. To add to the miseries, there have been a multitude of experimental treatments in the form of antivirals, immune-modulators, corticosteroids, etc., which can have serious interactions with psychotropic drugs. In this review, we intend to provide recommendations for pharmacotherapy to address the neuropsychiatric morbidity in COVID-19 patients.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed194    
    Printed10    
    Emailed0    
    PDF Downloaded27    
    Comments [Add]    

Recommend this journal